These advancements have the potential to significantly change how we treat metabolic diseases in the future
These decisions continue to have major implications on which corner of the life sciences tools and services space captures the most value: do the large bioprocessing platform players (e.g., Thermo Fisher, Cytiva, Sartorius) see an uplift, or do the specialized peptide synthesis equipment vendors and CDMOs benefit most (e.g., CEM Corporation, AAPPTec, Bachem, PolyPeptide)
and Caroline Apovian, MD , co-director at the Center for Weight Management and Wellness at Brigham and Women's Hospital
GLP-1 medications support weight loss by reducing cravings and quieting food noise
Dose modification represents a common management strategy